Business Wire

CA-NUCLEIX

29.10.2020 13:02:08 CET | Business Wire | Press release

Share
Nucleix’s Lung EpiCheck® Liquid Biopsy Test Detects 85% of Early Stage Lung Cancers in High-Risk Smokers, Study Published in European Respiratory Journal

Nucleix , a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced a publication showing its Lung EpiCheck® test detected 85% of early stage lung cancers among individuals at high risk for developing the disease based on their history of smoking. The study, entitled “Validation of Lung EpiCheck®, a novel methylation-based blood assay, for the detection of lung cancer in European and Chinese high-risk individuals,” was published online today ahead of print in the European Respiratory Journal (ERJ).

Lung EpiCheck analyzed 728 different samples in the study, including 311 from individuals with varying stages of lung cancer and 417 matched controls. By adjusting measurement of six methylation markers found in blood, the test was tailored to meet the needs of specific patient populations: increased sensitivity for high-risk populations, or increased specificity for low-risk populations. When focused on increased sensitivity for a high-risk population of past and current smokers, Lung EpiCheck demonstrated an overall sensitivity of 87% detection of lung cancer across all stages, 85% detection of Stages I-IIIA non-small cell lung cancer (NSCLC) and 78% detection of Stage I NSCLC, each with a specificity of 64%. The test also detected 100% of small cell lung cancer, a rapidly growing and deadly cancer that is typically challenging to detect. When focused on increased specificity for a low-risk population, Lung EpiCheck demonstrated overall specificity of 91% and sensitivity of 74%. Combining Lung EpiCheck with established risk factors improved the AUC, the ability to distinguish between patients with and without disease, from 88% to 94%.

“In the United States, very few high-risk individuals follow the recommended screening guidelines of annual, low-dose CT scans. Offering a highly sensitive test to those who decline to undergo the recommended scan gives them a better chance for early detection, while a false positive would simply result in proceeding to the current standard of care,” said Chris Hibberd, chief executive officer of Nucleix. “We are taking steps to further advance Lung EpiCheck as a low-cost blood test to encourage more patients to comply with recommended screening.”

Lung cancer is the deadliest cancer, with 1.76 million deaths worldwide in 2018.1 Survival hinges on early detection, with 5-year survival rates nearly 10 times greater for Stage I cancer than Stage IV cancer.2 The U.S. Preventive Services Task Force recommends annual screening with low-dose computed tomography (also called a low-dose CT scan, or LDCT) for current and past smokers at the highest risk of developing lung cancer – specifically, those individuals age 55-80 who have smoked an average of one pack of cigarettes a day for more than 30 years and currently smoke, or who quit, within the past 15 years.3 Even though there is no cost to these individuals to receive a LDCT scan, and it has been shown to improve survival,4 only 7%5 to 14%6 of those eligible in the United States follow this guideline due to a combination of inconvenience, missing infrastructure and fear of radiation exposure.

“Lung cancer is most often diagnosed at late stages when chances of cure are limited,” said Prof. Mina Gaga, Director and Head, 7th Respiratory Medicine Department, Athens Chest Hospital and the principal investigator of the study. “Tests for early diagnosis are urgently needed and the Lung EpiCheck data published in the ERJ show important promise for the implementation of lung cancer screening.”

Nucleix is continuing to optimize the Lung EpiCheck test and is advancing development of next-generation versions, with a goal of making a test available within 1 to 2 years.

About Lung EpiCheck®

Lung EpiCheck is designed to provide a simple blood test to detect lung cancer at its earliest stages. The test utilizes PCR-based technology for a low-cost analysis of subtle, disease-specific changes in DNA methylation markers. Lung EpiCheck is being developed for potential use in individuals with a history of smoking who are at high-risk of developing lung cancer, and do not comply with the guidelines for annual screening with LDCT scans. The test is not yet commercially available.

About Nucleix

Nucleix is a liquid biopsy company revolutionizing cancer treatment with earlier disease detection at a time when intervention can bring the greatest impact for patients. Leveraging PCR-based epigenetics, the Company’s pioneering testing approach uses methylation-based identification for early-stage and recurring cancer detection. The Company’s non-invasive EpiCheck® platform delivers highly accurate and sensitive results, all while providing a seamless testing option for patients and the healthcare system. The Company is building an EpiCheck franchise, beginning with the Bladder EpiCheck testing kit, marketed in Europe for bladder cancer recurrence. The Company is advancing a Lung EpiCheck test toward commercialization for high-risk individuals, while advancing additional tests for high-risk diseases. For more information, please visit: https://www.nucleix.com .


1 GLOBOCAN2018 Global Cancer Observatory http://gco.iarc.fr .
2 Lung cancer Stat Facts: Lung and Bronchus Cancer. https://seer.cancer.gov/statfacts/html/lungb.html entered October 2020.
3 https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening
4 NEJM Research team. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. N Engl J Med 2011;365:395-409.
5 LCSR Available Facility Reports. (n.d.). Retrieved October 28, 2020, from https://nrdrsupport.acr.org/support/solutions/articles/11000039783-lcsr-available-reports
6 Zahnd WE, Eberth JM. Lung cancer screening utilization: A behavioral risk factor surveillance system analysis. Am J Prev Med. 2019;57:250-255. doi: 10.1016/j.amepre.2019.03.015.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

WHOOP and Formula 1 Partner to Reveal the Human Performance Behind the Wheel18.11.2026 18:00:00 CET | Press release

Four-year global partnership makes WHOOP an Official Partner of Formula 1 bringing physiological insights into the broadcast beginning in 2027 WHOOP, the human performance brand, today announced a four-year global partnership with Formula 1, becoming the Official Health & Fitness Wearable Partner of Formula 1 and the first consumer wearable approved by the FIA for in-race use. Beginning in 2027, the partnership will bring continuous physiological monitoring to one of the world's most demanding sports, helping drivers and teams better understand how their bodies respond to the demands of competition while giving fans a new perspective on the human performance behind the wheel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118567291/en/ WHOOP and Formula 1 Partner to Reveal the Human Performance Behind the Wheel WHOOP is working to bring fans closer to the action than ever before, with Formula 1 integrating real-time physi

Future Health Launches Academy to Translate Life Sciences Advances Into Strategic Action18.11.2026 15:37:00 CET | Press release

Future Health Academy will build knowledge and connect expertise among health and life sciences professionals in Abu Dhabi and internationally. The Academy will support two-way knowledge exchange, bringing global expertise to Abu Dhabi while creating opportunities to share Abu Dhabi’s knowledge, expertise and innovation with the world. Inaugural course brought together senior leaders from government, healthcare, research, and industry with local and international scientific experts. Future Health - A Global Initiative by Abu Dhabi has launched the Future Health Academy as part of its year-round programme, designed to build knowledge, connect expertise and create opportunities for collaboration among health and life sciences professionals in Abu Dhabi and internationally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118051527/en/ The Future Health Academy will build knowledge and connect expertise among health and life s

Soracom Launches Physical AI Suite, Bringing Secure Connectivity and Remote Operations to Robots and Autonomous Machines18.11.2026 15:30:00 CET | Press release

Soracom suite combines existing platform services for physical AI, available worldwide Soracom, Inc. (TSE: 147A), a cloud-native IoT platform providing connectivity, cloud integration, and AI services for the Internet of Things, today announced Soracom Physical AI Suite, a set of Soracom platform services combined to connect, protect, and manage physical AI systems such as robots, autonomous mobile machines, and industrial equipment. Soracom Physical AI Suite is the company's second suite, following Soracom Automotive Suite announced in July 2026. Each suite brings together Soracom platform services commonly used for a particular type of deployment, organizing them into a single system. A team starting a new deployment begins from that system instead of selecting and assembling services one at a time. The suite is designed for companies that develop or deploy robots and other physical AI systems and for companies that operate connected equipment in industries including manufacturing, l

Variational Raises $110M Series B at $1.5B Valuation To Scale On-Chain Access To Global Markets18.11.2026 15:23:00 CET | Press release

The raise follows the rapid growth of swaps, Variational’s new instrument bringing liquidity from traditional finance on-chain. Variational, a protocol for on-chain derivatives trading, has announced a $110M Series B raise at a $1.5B valuation led by Bain Capital Crypto with support from Dragonfly, HSG, Peak XV, 50T Funds, and more. Since launching in early 2025, the platform has processed $475B+ in trading volume and accumulated $1.3B+ in open interest across 100k+ accounts. More than half of daily volume on the platform is now on traditional markets. The raise will fund the platform’s continued growth, allowing Variational to list hundreds more markets and lift open interest caps that traders increasingly hit. Omni, a trading platform built on Variational, offers leveraged trading on 550+ crypto and traditional markets. Unlike other on-chain trading platforms, Omni aggregates liquidity from both traditional and on-chain markets. This model allowed the platform to launch “swaps” in Se

Xsolla Connects Players, Brands, and Video Game Audiences Through Rewarded Engagement18.11.2026 15:00:00 CET | Press release

Players Can Choose Their Quests, Developers Get Measurable Results From Their Games, and Advertisers Get Verified Insight From Players Who Choose to Share Xsolla (USA), Inc., a global commerce company, announces Xsolla Ads, a rewarded marketing solution connecting brands with game audiences through quests players choose to take part in. Studios generate revenue beyond player purchases while brands drive measurable engagement, acquisition, and purchases. Players choose which campaigns to participate in and which rewards to receive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117947414/en/ Graphic: Xsolla Players see Xsolla Ads where they already are, including the Xsolla App, game web shops, branded pages on Xsolla, Xsolla Choice surveys, and an opt-in Offerwall. Quests are triggered by game events, such as reaching a new level or season, so studios connect campaigns to what players already do in their games. Completed

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye